Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin

Romidepsin is a histone deacetylase inhibitor approved by the FDA for the treatment of patients with cutaneous or peripheral T-cell lymphoma who have received prior systemic therapy. The objective of this analysis was to evaluate the potential QTc effects of romidepsin. Patients with advanced malign...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Sager, Philip T, Balser, Barbara, Wolfson, Julie, Nichols, Jean, Pilot, Richard, Jones, Suzanne, Burris, Howard A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2015
Gaiak:
Clinical Cancer Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4559029/
https://ncbi.nlm.nih.gov/pubmed/25914207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.467
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak